JP7100866B2 - メニエール病の処置法 - Google Patents

メニエール病の処置法 Download PDF

Info

Publication number
JP7100866B2
JP7100866B2 JP2018560665A JP2018560665A JP7100866B2 JP 7100866 B2 JP7100866 B2 JP 7100866B2 JP 2018560665 A JP2018560665 A JP 2018560665A JP 2018560665 A JP2018560665 A JP 2018560665A JP 7100866 B2 JP7100866 B2 JP 7100866B2
Authority
JP
Japan
Prior art keywords
composition
ebselen
subject
composition according
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018560665A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516727A (ja
JP2019516727A5 (enExample
Inventor
ジョナサン キール
Original Assignee
サウンド・ファーマシューティカルズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サウンド・ファーマシューティカルズ・インコーポレイテッド filed Critical サウンド・ファーマシューティカルズ・インコーポレイテッド
Publication of JP2019516727A publication Critical patent/JP2019516727A/ja
Publication of JP2019516727A5 publication Critical patent/JP2019516727A5/ja
Application granted granted Critical
Publication of JP7100866B2 publication Critical patent/JP7100866B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2018560665A 2016-05-18 2017-05-18 メニエール病の処置法 Active JP7100866B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662338443P 2016-05-18 2016-05-18
US62/338,443 2016-05-18
PCT/US2017/033379 WO2017201318A1 (en) 2016-05-18 2017-05-18 Treatment of meniere's disease

Publications (3)

Publication Number Publication Date
JP2019516727A JP2019516727A (ja) 2019-06-20
JP2019516727A5 JP2019516727A5 (enExample) 2020-06-25
JP7100866B2 true JP7100866B2 (ja) 2022-07-14

Family

ID=60326098

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018560665A Active JP7100866B2 (ja) 2016-05-18 2017-05-18 メニエール病の処置法

Country Status (20)

Country Link
US (1) US12427138B2 (enExample)
EP (2) EP3458045B1 (enExample)
JP (1) JP7100866B2 (enExample)
KR (1) KR102474830B1 (enExample)
CN (1) CN109475518B (enExample)
AU (1) AU2017267732B2 (enExample)
CA (1) CA3026007A1 (enExample)
CY (1) CY1127309T1 (enExample)
DK (1) DK3458045T3 (enExample)
ES (1) ES2990157T3 (enExample)
FI (1) FI3458045T3 (enExample)
HR (1) HRP20241559T1 (enExample)
HU (1) HUE069280T2 (enExample)
LT (1) LT3458045T (enExample)
PL (1) PL3458045T3 (enExample)
PT (1) PT3458045T (enExample)
RS (1) RS66167B1 (enExample)
SI (1) SI3458045T1 (enExample)
SM (1) SMT202400469T1 (enExample)
WO (1) WO2017201318A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220145879A (ko) 2020-02-24 2022-10-31 상하이테크 유니버시티 N-치환 피리딜벤즈이소셀라졸론 화합물의 용도
EP4452336A2 (en) * 2021-12-23 2024-10-30 University of Rochester Csf transport pathway for delivery of agents to inner ear
EP4536192A1 (en) 2022-06-06 2025-04-16 Sound Pharmaceuticals Incorporated Amorphous dosage form containing ebselen
EP4536191A1 (en) 2022-06-06 2025-04-16 Sound Pharmaceuticals Incorporated Ebselen containing oral dosage forms
WO2026073143A1 (en) * 2024-09-27 2026-04-02 Sound Pharmaceuticals Inc. Cochlear implant eluting ebselen for treating hearing loss

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005516028A (ja) 2002-01-04 2005-06-02 サウンド・ファーマシューティカルズ・インコーポレイテッド 難聴を治療する方法
US20110142834A1 (en) 2008-05-15 2011-06-16 Edison Pharmaceuticals, Inc. Treatment of hearing and balance impairments using compounds having erythropoietin activity
JP2014511374A (ja) 2011-02-04 2014-05-15 ハフ イヤ インスティテュート 外傷性脳損傷を処置する方法
US20150374779A1 (en) 2014-06-26 2015-12-31 Auris Medical Ag Pharmacologic treatments of meniére's disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3827093A1 (de) 1988-08-10 1990-02-15 Nattermann A & Cie Verfahren zur herstellung von hochreinem ebselen
DE68921436T2 (de) 1988-12-09 1995-08-10 Allergan Inc Verwendung von 2-substituierten Thiazolidin-4-carbonsäuren zur Behandlung von Katarakt.
US20070105782A1 (en) 2005-10-07 2007-05-10 Board Of Trustees Of Southern Illinois University Protectant Combinations for Reducing Toxicities
WO2008013866A2 (en) 2006-07-25 2008-01-31 Hough Ear Institute Methods for treating acute acoustic trauma
CA2732686C (en) 2008-12-22 2017-10-03 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
WO2013016727A1 (en) 2011-07-28 2013-01-31 Promentis Pharmaceuticals, Inc. Cysteine prodrugs
CN102526734A (zh) 2012-01-12 2012-07-04 王玉丰 治疗年龄相关性听力损失的药物组合物及其应用
EP3194027B1 (en) 2014-09-15 2026-02-11 Sound Pharmaceuticals Incorporated Compositions for use in treating psychotic disorders
KR20190024983A (ko) 2016-06-29 2019-03-08 오토노미, 인코포레이티드 트리글리세라이드 귀 제제 및 이의 용도
US10750005B2 (en) 2018-09-27 2020-08-18 International Business Machines Corporation Selective email narration system

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005516028A (ja) 2002-01-04 2005-06-02 サウンド・ファーマシューティカルズ・インコーポレイテッド 難聴を治療する方法
US20110142834A1 (en) 2008-05-15 2011-06-16 Edison Pharmaceuticals, Inc. Treatment of hearing and balance impairments using compounds having erythropoietin activity
JP2014511374A (ja) 2011-02-04 2014-05-15 ハフ イヤ インスティテュート 外傷性脳損傷を処置する方法
US20150374779A1 (en) 2014-06-26 2015-12-31 Auris Medical Ag Pharmacologic treatments of meniére's disease

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Equilibrium Research，2003年，62(2)，p.132-138
Expert Opin Investig Drugs，2015年，24(2)，p.201-217(page1-29)
Journal of the American Academy of Audiology，2007年，18(6)，p.522-529
Questionnaires to Measure Tinnitus Severity，ent and audiology news，2014年，22(6)，p.1-3
VALUE IN HEALTH，2007年，10(4)，p.273-284
日本耳鼻咽喉学会会報，2012年，115(9)，p.866-869

Also Published As

Publication number Publication date
PL3458045T3 (pl) 2025-01-07
CN109475518A (zh) 2019-03-15
JP2019516727A (ja) 2019-06-20
FI3458045T3 (fi) 2024-10-24
HRP20241559T1 (hr) 2025-02-14
EP3458045A4 (en) 2020-09-16
KR20190043499A (ko) 2019-04-26
ES2990157T3 (es) 2024-11-29
US12427138B2 (en) 2025-09-30
EP3458045B1 (en) 2024-08-21
HUE069280T2 (hu) 2025-02-28
KR102474830B1 (ko) 2022-12-06
SMT202400469T1 (it) 2025-01-14
CY1127309T1 (el) 2026-02-25
RS66167B1 (sr) 2024-12-31
LT3458045T (lt) 2024-12-10
US20200261417A1 (en) 2020-08-20
EP3458045A1 (en) 2019-03-27
SI3458045T1 (sl) 2025-03-31
PT3458045T (pt) 2024-10-28
AU2017267732A1 (en) 2018-12-20
CN109475518B (zh) 2026-05-08
CA3026007A1 (en) 2017-11-23
DK3458045T3 (da) 2024-11-04
EP4461360A2 (en) 2024-11-13
EP4461360A3 (en) 2025-01-22
WO2017201318A1 (en) 2017-11-23
AU2017267732B2 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
US10835546B2 (en) App specific BACE inhibitors (ASBIs) and uses thereof
JP2023169413A (ja) 精神病性障害を治療するための方法および組成物
JP2021502403A (ja) 遺伝性てんかん性障害の処置に使用するガナキソロン
CN109475518B (zh) 梅尼埃病的治疗
US20120252885A1 (en) Dronabinol treatment for migraines
EP2968235B1 (en) Combination of canagliflozin and probenecid for the treatment of hyperuricemia
TW202131910A (zh) 使用mtorc1調節劑的治療方法
JP2016509030A (ja) ニトライトの医薬製剤及びそれらの使用
AU2024204716A1 (en) Treatment of alopecia areata
US20220362189A1 (en) Combination therapy with acetyl-leucine and miglustat
US12419881B1 (en) Methods of using radiprodil in the treatment of disorders
JP2014513689A (ja) 過活動膀胱の治療のためのトロスピウムと唾液分泌刺激剤の組合せ
TW202535357A (zh) 治療更年期及近更年期之方法
EP4337212A1 (en) Use of complement factor d inhibitor for treatment of generalized myasthenia gravis
HK1257800B (en) Therapeutic uses of l-4-chlorokynurenine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200512

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210324

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210617

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220517

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220526

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220624

R150 Certificate of patent or registration of utility model

Ref document number: 7100866

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250